Psychedelic medicine, mental health research, and clinical trials by Definium Therapeutics
Definium Therapeutics unveils positive topline data from DT120 program at medical congress
Definium Therapeutics announced it is presenting positive topline data from its DT120 clinical program for the first time on a medical congress stage. The company will share a combined ...
Definium Therapeutics to report Q3 2026 financials following momentum in late stage trials
Definium Therapeutics announced it will report its third quarter 2026 financial results and recent business updates in the near future. The company said this follows a year marked by significant ...
Definium Therapeutics advances Phase 3 trials for DT120 in major depressive disorder and anxiety
Definium Therapeutics announced that Chief Medical Officer Dan Karlin presented new information on the company’s Phase 3 studies evaluating DT120 for major depressive disorder and generalized ...
Definium Therapeutics secures top poster award at PsychCongress for DT120 Phase 3 results
Definium Therapeutics has received the 2026 Poster Award for Excellence in Psychiatry at PsychCongress, recognizing its Phase 3 topline results for DT120 in generalized anxiety disorder. The study ...
Definium Therapeutics reports positive Phase 3 Panorama results for DT120 ODT in GAD
Definium Therapeutics has announced positive topline results from its Phase 3 Panorama study evaluating DT120 ODT for generalized anxiety disorder (GAD). The company highlighted that this ...
Definium Therapeutics targets accelerated progress in mental health innovations at September investor events
Definium Therapeutics is building on recent milestones by participating in key investor events this September. The company aims to advance scientific rigor and accelerate the development of ...
Definium Therapeutics advances pivotal Phase 3 Voyage trial in generalized anxiety disorder
Definium Therapeutics has moved forward with its pivotal Phase 3 Voyage trial targeting generalized anxiety disorder (GAD), aiming to set higher expectations for both patients and clinicians in ...
Definium Therapeutics advances in pivotal study with fresh Phase 3 anxiety data
Definium Therapeutics reported positive topline results from its first Phase 3 clinical trial, Voyage, evaluating DT120 ODT for generalized anxiety disorder. This marks the companys second ...
Definium Therapeutics reports Q2 2026 results as momentum builds for psychiatric disorder treatments
Definium Therapeutics has released its financial results for the second quarter of 2026, highlighting a year of sustained momentum for the company. The report details significant progress on ...
Definium Therapeutics schedules next earnings announcement amid ongoing progress
Definium Therapeutics has announced plans to report its second quarter 2026 financial results and business updates on August 6, 2026. The company highlighted continued progress throughout the ...
Definium Therapeutics posts positive topline data from Phase 3 Emerge trial for major depressive disorder
Definium Therapeutics announced positive topline results from its Phase 3 Emerge clinical trial, marking a key development for the company and the broader mental health therapeutics landscape. ...
Definium Therapeutics reports breakthrough with Emerge trial for LSD-based depression therapy
Definium Therapeutics announced today that its Emerge study, the first Phase 3 clinical trial for its pharmaceutical LSD in major depressive disorder (MDD), delivered positive topline results. ...
Definium Therapeutics examines neuroplasticity and psychedelics potential to disrupt negative brain cycles
Definium Therapeutics is exploring the intersection of neuroplasticity and psychedelics, focusing on whether these substances can break cycles of negative brain activity. Rakesh Jain, MD, MPH, ...
Definium Therapeutics leadership to appear at Jefferies Healthcare Conference with CEO, CMO, and CFO
Definium Therapeutics has announced that its executive team will participate in a fireside chat at the Jefferies Healthcare Conference this Wednesday, June 3. The session will feature CEO Robert ...
Definium Therapeutics unveils AI-driven advances at ASCP event in Miami Beach
Definium Therapeutics presented new developments in artificial intelligence applications for psychiatric drug development at the American Society of Clinical Psychopharmacology (ASCP) Annual ...
Definium Therapeutics convenes lawmakers and researchers to advance psychedelic medicine discourse
Definium Therapeutics brought together lawmakers, clinical researchers, and advocates in the nation's capital to focus on ongoing research in psychedelic medicines and the future direction of ...
Definium Therapeutics presents pre-clinical safety data on new psychedelic treatment at APA meeting
Definium Therapeutics presented scientific posters featuring pre-clinical safety data for its investigational psychedelic treatment at the American Psychiatric Association (APA) Annual Meeting. ...
Definium Therapeutics launches pivotal Phase 3 Ascend trial in major depressive disorder
Definium Therapeutics has announced the dosing of the first patient in its Ascend study, marking the start of the company’s second Phase 3 pivotal trial targeting major depressive disorder ...
Definium Therapeutics engages at Fierce Biotech Week with industry communications leaders
Definium Therapeutics is participating in Fierce Biotech Week, with its Chief Corporate Affairs Officer, Stephanie Fagan, taking part in a panel discussion. She is joined by Debbie Etchison, ...
